CDX 1135

Drug Profile

CDX 1135

Alternative Names: BRL 55730; CDX-1135; sCR1; Soluble complement receptor 1; Soluble complement receptor type 1; Soluble CR1; TP 10HD; TP10; YM 203

Latest Information Update: 15 Apr 2014

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer Celldex Therapeutics Inc
  • Class Anti-ischaemics; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allotransplant rejection; Disseminated intravascular coagulation; Lung transplant rejection; Membranoproliferative glomerulonephritis; Multiple sclerosis; Reperfusion injury; Rheumatoid arthritis; Systemic lupus erythematosus; Xenotransplant rejection

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Apr 2014 Discontinued - Phase-I for Membranoproliferative glomerulonephritis in USA (IV)
  • 15 Apr 2014 Discontinued - Phase-II for Allotransplant rejection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top